These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10981147)

  • 1. Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence.
    August P; Leventhal B; Suthanthiran M
    Curr Hypertens Rep; 2000 Apr; 2(2):184-91. PubMed ID: 10981147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor beta and progression of renal disease.
    August P; Suthanthiran M
    Kidney Int Suppl; 2003 Nov; (87):S99-104. PubMed ID: 14531781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor beta and excess burden of renal disease.
    August P; Sharma V; Ding R; Schwartz JE; Suthanthiran M
    Trans Am Clin Climatol Assoc; 2009; 120():61-72. PubMed ID: 19768163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients.
    Suthanthiran M; Khanna A; Cukran D; Adhikarla R; Sharma VK; Singh T; August P
    Kidney Int; 1998 Mar; 53(3):639-44. PubMed ID: 9507209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage.
    Suthanthiran M; Li B; Song JO; Ding R; Sharma VK; Schwartz JE; August P
    Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3479-84. PubMed ID: 10725360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans.
    Suthanthiran M; Gerber LM; Schwartz JE; Sharma VK; Medeiros M; Marion R; Pickering TG; August P
    Kidney Int; 2009 Jul; 76(1):72-80. PubMed ID: 19279557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes.
    Flack JM; Hamaty M
    J Hypertens Suppl; 1999 Feb; 17(1):S19-24. PubMed ID: 10340840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.
    Jamerson KA
    Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S24-30. PubMed ID: 10986156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of hypertension in African Americans.
    Ferdinand KC; Armani AM
    Crit Pathw Cardiol; 2007 Jun; 6(2):67-71. PubMed ID: 17667868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage.
    Flack JM; Mensah GA; Ferrario CM
    Curr Med Res Opin; 2000; 16(2):66-79. PubMed ID: 10893650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta in hypertensives with cardiorenal damage.
    Laviades C; Varo N; Díez J
    Hypertension; 2000 Oct; 36(4):517-22. PubMed ID: 11040229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
    Toto RD
    Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race and hypertensive target-organ damage in patients from an university-affiliated outpatient care referral clinic in the city of Salvador.
    Noblat AC; Lopes MB; Lopes AA
    Arq Bras Cardiol; 2004 Feb; 82(2):116-20, 111-5. PubMed ID: 15042247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction.
    Arora R; Clark L; Taylor M
    J Clin Hypertens (Greenwich); 2003; 5(1 Suppl 1):26-31. PubMed ID: 12556670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting racial differences in ESRD due to ADPKD in the United States.
    Murphy EL; Dai F; Blount KL; Droher ML; Liberti L; Crews DC; Dahl NK
    BMC Nephrol; 2019 Feb; 20(1):55. PubMed ID: 30764782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?
    Whittle JC; Whelton PK; Seidler AJ; Klag MJ
    Arch Intern Med; 1991 Jul; 151(7):1359-64. PubMed ID: 2064486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans.
    Freedman BI; Yu H; Spray BJ; Rich SS; Rothschild CB; Bowden DW
    Kidney Int; 1997 Mar; 51(3):819-25. PubMed ID: 9067916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension.
    McClellan W; Tuttle E; Issa A
    Am J Kidney Dis; 1988 Oct; 12(4):285-90. PubMed ID: 3263042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of transforming growth factor-beta1 in essential hypertension.
    Derhaschnig U; Shehata M; Herkner H; Bur A; Woisetschläger C; Laggner AN; Hirschl MM
    Am J Hypertens; 2002 Mar; 15(3):207-11. PubMed ID: 11939608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.